BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu I, Chen L, Ruan JY, Chang JT, Cheung WY. Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients. Support Care Cancer 2016;24:1199-208. [PMID: 26286113 DOI: 10.1007/s00520-015-2899-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Kim JH, Kim JE, Hong YS, Kim SY, Kim KP, Choi KE, Shin JH, Kim TW. Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab: A single-institutional experience. Chin J Cancer Res 2018;30:460-7. [PMID: 30210226 DOI: 10.21147/j.issn.1000-9604.2018.04.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Zhang J, Zhang HY, Li J, Shao XY, Zhang CX. The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget 2017;8:68837-46. [PMID: 28978160 DOI: 10.18632/oncotarget.18575] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
3 Gerotziafas GT, Elalamy I. [Risk of venous thromboembolism in cancer patients: Reality, actuality and perspectives]. Bull Cancer 2016;103:764-75. [PMID: 27481723 DOI: 10.1016/j.bulcan.2016.07.001] [Reference Citation Analysis]
4 Wang YH, Deng SJ, Yang YD, Yao N, Zhao JM, Min GT, Wang J, Xu TF, Zhao PY, Wang HP, Chen W. The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Biomark Med 2017;11:195-210. [PMID: 28097884 DOI: 10.2217/bmm-2016-0214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]